An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| |
| Authors: | Ramzi M Mohammad Jack Wu Asfar S Azmi Amro Aboukameel Angela Sosin Sherwin Wu Dajun Yang Shaomeng Wang Ayad M Al-Katib |
| |
| Affiliation: | (1) Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R Street, Detroit, Michigan 48201, USA;(2) Detroit Country Day School, Beverly Hills, Michigan, Michigan, USA;(3) Department of Internal Medicine, University of Michigan, USA;(4) Ascenta Therapeutics, Inc, Malvern, Pennsylvania, USA |
| |
| Abstract: | Background MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
